Validationofthep21-ActivatedKinasesasTargetsforInhibitioninNeurofibromatosisType2ChunlingYi,1ErikW.Wilker,2MichaelB.Yaffe,2AnatStemmer-Rachamimov,3andJosephL.Kissil11MolecularandCellularOncogenesisProgram,TheWistarInstitute,Philadelphia,Pennsylvania;2CenterforCancerResearch,MassachusettsInstituteofTechnology,Cambridge,Massachusetts;and3DepartmentofPathology,MassachusettsGeneralHospital,Boston,MassachusettsAbstractNeurofibromatosistype2(NF2)isadominantlyinheritedcancerdisordercausedbymutationsattheNF2genelocus.Merlin,theproteinproductoftheNF2gene,hasbeenshowntonegativelyregulateRac1signalingbyinhibitingitsdownstreameffectorkinases,thep21-activatedkinases(Pak).GiventheimplicationofPaksintumorigenesis,itisplausiblethatmerlin’stumorsuppressivefunctionmightbemediated,atleastinpart,viainhibitionofthePaks.Wepresentdataindicatingthisisindeedthecase.First,analysisofprimaryschwannomasamplesderivedfromNF2patientsshowedthatinasignificantfractionofthetumors,theactivityofPak1washighlyelevated.Second,weusedshRNAstoknockdownPak1,2,and3inNIH3T3cellsexpressingadominant-negativeformofmerlin,NF2BBA(NIH3T3/NF2BBA),andfindthatsimultaneousknockdownofPak1-3inthesecellssignificantlyreducedtheirgrowthratesinvitroandinhibitedtheirabilitytoformtumorsinvivo.Finally,whileattemptingtosilencePak1inratschwannomacells,wefoundthatthesecellswereunabletotoleratelong-termPak1inhibitionandrapidlymovedtorestorePak1levelsbyshuttingdownPak1shRNAexpressionthroughamethylation-dependentmechanism.ThesedatasuggestthatinhibitingPakcouldbeabeneficialapproachforthedevelopmentoftherapeuticstowardNF2.Inaddition,thefindingthattheshRNA-mediatedPak1suppressionwassilencedrapidlybymethylationraisesquestionsaboutthefutureapplicationofsuchtechnologiesforthetreatmentofdiseasessuchascancer.[CancerRes2008;68(19):7932–7]IntroductionThehallmarkofneurofibromatosistype2(NF2),whichaffects1in30,000to40,000ofthepopulation,isthedevelopmentofbilateralvestibularschwannomas(VS)attheeighthcranialnerve.MostNF2patientsgoontodevelopmultiplecranialandspinalschwannomas,meningiomas,andlessfrequently,intraspinalependymomas,withsymptomsincludingauditory,visual,andmotorimpairments.Currently,riskysurgicalexcisionistheonlytreatmentoption,andthetumorswillinevitablyrecur,leadingtoahighearlymortalityrateamongNF2patients(1).Merlin,theproteinencodedbytheNF2gene,iscloselyrelatedtotheERM(ezrin,radixin,andmoesin)proteins,containinganNH2-terminalFERMdomainfollowedbyacoiled-coildomain.Thecarboxyl-terminaldomain(CTD)ofmerlinisuniqueandlackstheconventionalactin-bindingmotiffoundinERMproteins.MerlinCTDcanassociatewithitsNH2-terminalFERMdomain,forminga‘‘closed’’andfunctionallyactiveconfiguration.Phosphorylationofmerlinatserine518disruptsthisintramolecularinteractionandsuppressesitsgrowthinhibitoryactivity.Thisphosphorylationismediatedbyp21-activatedkinases(Pak),whichbindtoactivated(GTPbound)Rac/Cdc42andfunctionastheirdirecteffectors(2,3).Inaddition,ithasbeenshownthatmerlinS518canalsobephosphorylatedbythecyclicAMP-dependentproteinkinase(PKA),whereasitsdephosphorylationinvolvesthemyosinphosphataseMYPT-1-PP1y(4,5).SeverallinesofevidenceindicatethatmerlinisnotonlyregulatedbytheRac-PakaxisbutalsofunctionsasaninhibitorofRacsignaling.Specifically,merlinoverexpressionsuppressesRac1-inducedactivationofc-Jun-NH2-terminalkinaseandactivatorprotein–1transcriptionalactivity,whereaslossofmerlinresultsintheopposite(6).Inaddition,merlininhibitionviadominant-negativemutantsorsiRNAenablesRac1recruitmenttoplasmamembraneandalleviatescontactinhibitioninconfluentcells(7).Furthermore,increasedlevelsofactivatedRacwithdisruptedtemporalcontrolhavebeenreportedinprimaryNF2-mutantschwannomacells(8,9).Finally,merlinoverexpressioninSchwanncellssuppressesPak1activity,whereasablationofmerlininMEFsleadstoPak1activation(7,10,11).TheinhibitoryactivityofmerlintowardPak1hasbeenattributedtoitsdirectinteractionwiththeRac-bindingdomainofPak1,whichinterfereswiththebindingofactivatedRactoPak1(10,12).Inthisstudy,weexaminewhetherinhibitingPakcanreversethetransformedandcancerphenotypesthatarisefromNF2deficiency.WefindthatPak1ishyperactiveinprimaryschwannomasisolatedfromNF2patientsandthatsuppressionofthePaksviashRNAsreducestheabilityofNF2mutantcellstogrowinvitroandformtumorsinaxenograftmodelofNF2.MaterialsandMethodsSchwannomabiopsies.FrozentissuesamplesfromNF2patientsthatunderwentsurgeryinMassachusettsGeneralHospital(MGH),werereceivedfromtheMGHBrainTumortissuerepository,undertheapprovaloftheMGHInstitutionalReviewBoard.Two-dimensionalgelanalysis.Frozentumorsamplesweremincedandproteinwasextractedinsamplebuffer(9.8mol/LUrea,2%CHAPS,5Al/mL0.5%IPGbufferpH4–7,DTT15mg/mL).Allsubsequentstepswereperformedaspreviouslydescribed(10).Cellcultureconditions.RT4andNIH3T3cellsweregrowninlow-glucoseDME,10%FCS,1nonessentialaminoacids,and100IU/mLpenicillin-streptomycin.TransfectionswereperformedwithLipofect-amine2000(Invitrogen),followingmanufacturer’sinstructions.ToinhibitDNAmethylation,5-aza-2¶-deoxycytidine(5-aza;Sigma)wasaddedtothemedia(5ng/mL).Note:SupplementarydataforthisarticleareavailableatCancerResearchOnline(http://cancerres.aacrjournals.org/).Requestsforreprints:JosephL.Kissil,WistarInstitute,3601SpruceStreet,Philadelphia,PA19104.Phone:215-898-3874;Fax:215-898-3792;E-mail:jkissil@wistar.org.I2008AmericanAssociationforCancerResearch.doi:10.1158/0008-5472.CAN-08-0866CancerRes2008;68:(19).October1,20087932www.aacrjournals.orgResearchArticleResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from KnockdownofPak1,2,and3usinglentiviraldeliveredshRNAs.ForsilencingendogenousPak1,2,and3inNIH3T3andRT4cells,severalsequencesweretestedandthefollowingtargetingsequenceswereselectedbasedontheirknockdownefficiency:Pak1,‘‘5¶-GGATTCTGTGCACAGA-TAA’’and‘‘5¶-GGAATGGATGGCTCTGTCA’’;Pak2,‘‘5¶-GAGATTATGGA-GAAATTAA’’;Pak3,‘‘5¶-GGAATTAATTATTAATGAA.’’DNAoligoscontainingindividualtargetingsequenceswereclonedintopLenti-lox3.7(pLL3.7)aspreviouslydescribed(13).TheresultingvectorswerecotransfectedwithpackagingvectorsVSVGandD8.9into293Tcellsandviralsupernatantwascollected48and72hposttransfection.Forinfection,cellswereincubatedwiththeviralsupernatantovernightandinfectedcells[greenfluorescentprotein(GFP)positive]wereselectedbyflowcytometry.Westernblotanalysis.Proteinextractswerepreparedwithradio-immunoprecipitationassaybuffer[50mmol/LTRIS-HCl(pH7.5),1%NonidetP-40,0.25%sodiumdeoxycholate,150mmol/LNaCl,1mmol/LEGTA,1mmol/Lsodiumorthovanadate,and1mmol/LNaF].Thefollowingantibodieswereusedaccordingtomanufactures’instructions:Pak1(N-20),Pak3(N-19),merlin(C-18;SantaCruz);Pak2(2608;CellSignaling);anda-tubulin(AC42)andh-actin(AC40;Sigma).Cellproliferationassays.Thirtythousandcellsperwellwereplatedin12-welldishesintriplicateforeachcellline.Atindicatedtimepoints,cellsfromindividualwellsweretrypsinizedandcountedusingaCoultercounter(Z1series;BeckmanCoulter).Cellswerefedevery3dthroughouttheassay.StatisticalanalysiswasperformedusingStudent’sttest.Tumorigenicityassays.Cellsweretrypsinized,washed,andresus-pendedat107cells/mLinPBS.Cells(106;100AL)wereinjecteds.c.intotheflanksof5-wk-oldnudemice(BALB/cnu/nu;TheJacksonLaboratory).Miceweremonitoredandtumordiametersweremeasuredweeklyafterinjections.Bisulfitesequencing.GenomicDNAwasfirstdigestedwithSacI,precipitated,anddissolvedindouble-distilledwater(ddH2O).Onemicroliterof6NNaOHwasaddedto19ALddH2Ocontaining2AgofthedigestedDNA,andincubatedat37jCfor15¶.Subsequently,120ALbisulfiteconversionsolution(107AL4.04MNaHSO3,7AL10mmol/LHydroquinone,and6AL6NNaOH)wasaddedtotheDNAsolution,andbisulfiteconversionwascarriedout(30"at95jCfollowedby15¶at50jCfor15cycles).Bisulfite-treatedDNAwasthendesalted(WizardDNAcleanupkit;Promega)andelutedin50ALTEbuffer.6NNaOH(2.5AL)wasaddedtotheelutedDNAandincubatedatRTfor5¶.DNAwasprecipitatedandresuspendedin30ALddH2O.Onemicroliterwasusedastemplateina20ALnestedPCRreactionwiththefollowingprimers:‘‘5¶-TTTAAAA-GAAAAGGGGGGATT’’and‘‘5¶-TCTCAAAACACACAATTACT.’’Onemicroli-terofthefirstroundwasusedastemplateforasecondroundofPCRusingthenestedprimers:‘‘5¶-AGGGGAAAGAATAGTAGATATAA’’and‘‘5¶-TTAAC-CRAAACAAAAAATAACC.’’TheresultingPCRproductwaspurifiedandsequencedusingprimer‘‘5¶-AGGGGAAAGAATAGTAGATATAA.’’Senescence-associatedB-Galassay.CellswerewashedthricewithPBSandfixedwith0.2%glutaraldehydefor5¶.AfterthreewasheswithPBS,cellswereincubatedovernightwithX-galsolution[1mg/mLX-gal,150mmol/LNaCl,2mmol/LMgCl2,5mmol/LK3Fe(CN)6,5mmol/LK4Fe(CN)6,and40mmol/LNaPi(pH6.0)at37jC].ResultsElevatedlevelsofPak1activityinprimaryschwannomatumorsamples.TheactivationofPak1involvesitsphosphoryla-tionatmultiplesites(10,14,15).Wehavepreviouslyestablishedatwo-dimensionalgelapproachtomonitorthephosphorylationstateofPak1,whichhasbeenshowntoaccuratelyreflecttheactivationstateofPak1inthecell(7,10).Byuseofthisapproach,weexaminedthestatusofPak1inprimaryschwannomasamplesisolatedfromNF2patients.Myelinatednervefromapatientwithwild-typeNF2wasusedascontrol.AsshowninFig.1A,Pak1migratesasasinglespottowardtheneutralpHrangein‘‘normal’’myelinatednerve,indicatingthatPak1ismostlyunphosophory-lated/inactive.Incontrast,withtheexceptionofsamplext3224,18ofthe19schwannomasamplesweanalyzeddisplayedvariousformsofphosphorylatedPak1(Fig.1AandB),indicativeofFigure1.Pak1isactivatedinschwannomasfromNF2patients.A,analysisofPak1activationbytwo-dimensionalgelelectrophoresiscoupledtoWesternblotanalysis.Arrowheads,variousphosphorylatedformsofPak1.B,summaryofPak1phosphorylationstatusinprimaryschwannomas.Allsampleswerenormalizedforvariationsinsampleloadingbycomparisontoactinasaninternalstandard.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7933CancerRes2008;68:(19).October1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Pak1activation.In6ofthe19samples,asexemplifiedbysamplext1441,themajorityofthePak1proteinsexistedinhighlyacidicforms,suggestiveofhyper-phosphorylation(Fig.1AandB).In12ofthe19samples,multipleformsofhypophosphorylatedorhyper-phosphorylatedPak1werepresent,asrepresentedbysamplext1729.ThesedatasuggestthatinprimarytumorsfromNF2patients,Pak1existsinaphosphorylated/activatedform.ThisisconsistentwithpreviousfindingsthatmerlinactsasadirectinhibitorofPak1(7,10).shRNA-mediateddepletionofPak1,2,and3inhibitstheproliferationandtumorigenicityofNIH3T3/NF2BBAcells.WehavepreviouslyshownthatexpressionofNF2BBA,adominant-negativeformofmerlin,inNIH3T3cellsinducedtransformation,lossofcontactinhibition,andtumorformationwheninjectedinnudemice(16).BecausePak1isthemostabundantmemberofthePakfamilyinNIH3T3cells,wefirstexaminedtheeffectofPak1inhibitioninthesecells.Weinfectedwild-typeNIH3T3orNIH3T3/NF2BBAcellswitheitheranemptylentiviralvectororvectorsharboringPak1-specificsmallhairpinRNAs(shRNA)andselectedinfected(GFPpositive)cellsbyflowcytometry.AsshowninFig.2A,Pak1proteinlevelsweresignificantlyreducedincellsinfectedwithlentivirusescarryingPak1shRNAs.Followingthegrowthkineticsofthesefourdifferentcelllines,wefoundthat,consistentwithpreviousfindings,NIH3T3/NF2BBAcellsgrowfasterthanwild-typeNIH3T3cells(Fig.2B).However,weobservednosignificantdifferencesingrowthratesbetweencellsinfectedwithemptyvectorsandthosewithPak1shRNAs(Fig.2B).WeinjectedthesefourcelllinesintonudemiceandfoundthatNIH3T3/NF2BBAcellsexpressingPak1shRNAsstilldevelopedtumorsofsimilarsizecomparedwithcontrolNIH3T3/NF2BBAcells(Fig.2C).Therefore,inhibitionofPak1aloneisnotsufficienttocountertheeffectofmerlinimpairmentinNIH3T3/NF2BBAcells.SimilarresultswereobtainedwheneitherPak2orPak3wasknockeddownindividuallyinNIH3T3/NF2BBAcells(SupplementaryFig.S1).BecausePak1,2,and3sharehighsequencehomologies,wereasonedthatthelossofindividualPakislikelycompensatedbytheothertwomembersofPaks.Toinvestigatethispossibility,weinfectedNIH3T3withlentivirusescarryingshRNAsspecificforPak1,Pak2,andPak3.AsshowninFig.3A,theseNIH3T3cellsshowedsignificantreductionofallthreePaks.WecharacterizedtherespectiveproliferationkineticsofNIH3T3andNIH3T3/NF2BBAcellsinfectedwithcontrollentivirusesorthoseexpressingshRNAsagainstPak1to3.IncontrasttothelackofeffectobservedinPak1ablationalone,knockdownofallthreePaksdramaticallyreducedthegrowthratesoftheNIH3T3/NF2BBAcells(Fig.3B;Supplemen-taryFig.S1),indicatingthatdepletionofallthreePakssuccessfullyreversedthehyperproliferativeeffectofmutantmerlininourcellularmodel.KnockdownofPak1-3alsodecreasedtheprolifer-ationrateofwild-typeNIH3T3cells,buttoamuchlesserextend,comparingtothedramaticeffectsobservedintheNIH3T3/NF2BBAcells(Fig.3B).WenextinjectedNIH3T3/NF2BBAcellscarryingemptyvectorsorPak1-3shRNAssidebysideintotheflanksofnudemiceandfollowedthedevelopmentoftumorsoverthecourseofseveralweeks.Inagreementwithourpreviousstudy(16),thecontrolNIH3T3/NF2BBAcells(leftflanks)quicklydevelopedintotumors,reachinganaveragediameterof160mmby3weekpostinjection(Fig.3C;SupplementaryTableS1).Incomparison,NIH3T3/NF2BBAcellsexpressingPak1-3shRNAs(rightflanks)resultedineithernotumorsormuchsmallertumorsataconsiderablydelayedrate.Theaveragediameteroftumorsthateventuallydevelopedfromthesecellswascloseto10mmat3weekspostinjection(Fig.3C;SupplementaryTableS1).TheseresultsindicatethatsimultaneoussuppressionofallthreePakscanatleastpartiallyinhibittheabilityofNf2BBAtoinducetumorformationinaxenograftmodelofNF2,whichcorroborateourhypothesisthatinhibitingPakscouldserveasapotentialtreatmentforNF2.ToinvestigatewhatcausedtheeventualdevelopmentofsmalltumorsfrominjectedNIH3T3/NF2BBAcellsexpressingPak1-3shRNAsinsomeofthemice,weisolatedthetumorsfrombothflanksofthesemiceandexaminedtheexpressionlevelsofPak1,2,and3.AsshowninFig.3D,intwoofthemiceexamined(#7007and#7049),theexpressionofatleasttwoofthePakswaspartiallyrestoredtosimilarlevelsofthoseintumorsfromcontrolNIH3T3/NF2BBAcells.Thismayexplainwhythesecellsdideventuallyformtumors.Inathirdmouse(#7045),thelevelsofallthreePaksFigure2.Pak1knockdownonNIH3T3cellsisinsufficienttoinhibitcelltransformationduetoimpairedNF2function.NIH3T3(WT)orNIH3T3/NF2BBA(NF2BBA)cellswereinfectedwithemptylentiviruses(Lenti)orlentivirusesharboringPak1shRNAs(Lenti-Pak1sh).A,Pak1expressionlevelsweredeterminedbyWesternblotanalysis.Actinwasusedasaninternalstandard.B,cellularproliferationkinetics.Cells(3104)fromeachofthecelltypesabovewereplatedintriplicateinto12-wellplates.Cellswereharvestedandcountedatday0,1,2,3,and4.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.C,tumorformationcapability.Cells(106)wereinjectedintotherearflanksofseverecombinedimmunodeficientmice.Fourmicewereusedforeachcellline.Tumorsweremeasured15dafterinjections.CancerResearchCancerRes2008;68:(19).October1,20087934www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from remainedlowinthetumordevelopedfromPak-shRNAexpressingNIH3T3/NF2BBAcells(Fig.3D),indicatingthatadditionalmecha-nismsinvolvedinoffsettingthelossofPakinthesecells.SchwannomacellsaredependentonPak1andsilencePak1shRNAexpressionviadenovomethylation.BecauseNF2patientsprimarilydevelopSchwanncelltumors,wenextexaminedtheeffectofPakknockdowninawell-characterizedratschwannnomacellline,RT4.UnlikeNIH3T3cellsinwhichallthreePaksareexpressed,RT4cellsexpresspredominantlyPak1(SupplementaryFig.S2).WeinfectedRT4cellswithlentivirusescarryingthesamePak1-specificshRNAsthatwereusedinNIH3T3cells(Figs.2and3),andasexpected,RT4cellsshowedsignificantlyreducedPak1expressionaftertheinfection(Fig.4A).However,thePak1levelsinRT4cellsinfectedwithPak1shRNAswerequicklyrestored,withintwotothreepassages,tosimilarlevelsfoundincontrolRT4cells(Fig.4A).Correspondingly,theexpressionlevelofGFP,apositiveselectionmarkerinthelentiviralvector,pLenti-lox3.7,intowhichPak1shRNAswerecloned,droppedrapidlyduringthefirsttwotothreepassagesoftheinfectedRT4cells(Fig.4A).GiventherapidnatureofrestorationinPak1levelsandconcurrentdown-regulationofGFPexpression,wesuspectedthatRT4cellsmighthaveusedanepigeneticmechanism,namelyDNAmethylation,tosilencePak1shRNAexpressionandrestorelevelsofPak1.Totestwhetherthisisindeedthecase,wecarriedoutbisulfitesequencingtodirectlyexaminethemethylationstatusonthef200bppromoterregioninpLenti-lox3.7thatdrivesPak1shRNAexpression.AsshowninFig.4B,multipleCpGsiteswereindeedmethylatedwithinthisrelativelysmallregioninhighpassageRT4cellscarryingpLenti-Pak1shRNAs.TofurtherconfirmthatmethylationisresponsibleforsilencingPak1shRNAexpression,weaddedthemethylationinhibitor5-azaintothecellculturemediumofRT4cellscarryingemptyvectorsorPak1shRNAs,whichhadbeenpassedatleast8timesanddisplayedsimilarPak1expressionlevels(Fig.4C).Thecellswereculturedforseveraldaysinthepresenceof5-aza,andPak1expressionlevelswereexaminedatdifferenttimepoints.Incontrasttowhatweobservedwiththesecellswithout5-azatreatment(Fig.4A),afteronlyasingledayof5-azatreatment,Pak1levelsweresignificantlyloweredinRT4cellscarryingPak1shRNAswhencomparedwithcontrolRT4cells(Fig.4C).WewereabletosustainthissuppressionofPak1expressionforatleast3daysoftreatment(Fig.4C).Thus,RT4cellsevadePak1inhibitionbyshuttingdownPak1shRNAexpressionthroughmethylationofthepLenti-lox3.7promoter.WethenmeasuredthegrowthratesofRT4cellscarryingemptyvectorsorPak1shRNAsinthepresenceorabsenceof5-aza.Intheabsenceof5-aza,RT4cellsinfectedwithPak1shRNAsshowedonlyslightlyreducedgrowthratecomparedwithcontrolRT4cells(Fig.4D).Inthepresenceof5-aza,controlRT4cellsgrewrelativelyslowerthanuntreatedcells(Fig.4D).Thisisnotsurprising,consideringthat5-azaisaglobalmethylationinhibitor.Insharpcontrast,however,RT4cellscarryingPak1shRNAscompletelyfailedtogrowundercultureconditionsthatincluded5-aza(Fig.4D).Thedifferenceisalsoobviousinthemorphologiesofthesecells.Comparedwiththemostlyspindle-shapeduntreatedor5-aza–treatedcontrolRT4cells,thePak1-shRNA–infectedRT4cellsgrowninthepresenceof5-azaareenlargedandflattened,displayingamorphologyconsistentwithcellularsenescence(Fig.4E).Thesecellsalsostainedpositiveforthesenescence-associatedexpressionofh-galactosidaseactivity,indicatingthatFigure3.KnockdownofPak1-3issufficienttoinhibitcellulartransformationduetoimpairedNF2function.TheeffectsofsimultaneousPak1+2+3knockdownwereexaminedinNIH3T3orNIH3T3/NF2BBAcellsinfectedwithemptylentivirusorlentivirusesharboringPak1+2+3shRNAs.A,WesternblotanalysisofPak1,2,and3levels.Actinwasusedasaninternalstandard.B,assessmentofcellularproliferation.Cells(3104)wereplatedintriplicateinto12-wellplates.Cellswereharvestedandcountedatday0,1,2,3,4,5,and6.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.C,tumorsizedistributioninseverecombinedimmunodeficientmice.Tumorformationwasassessedbyinjecting5105NIH3T3-NF2BBAcellsinfectedwithemptyvirus(Lenti)intotheleftflanksand5105ofNIH3T3/NF2BBA-Lenti-PAK1-3shintotherightflanksofthesamemice.Fivemicewereusedintotal.Thesizeoftumorswasmeasured23dafterinjection.Horizontallines,averagetumordiameters.D,Westernblotanalysisoftumorsdissectedfrommice#7007,#7045,and#7049.L,tumorsfromleftflankarisingfromNIH3T3/NF2BBA/Lenticells;R,tumorsfromrightflankarisingfromNIH3T3/NF2BBA/Lenti-PAK1-3shcells.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7935CancerRes2008;68:(19).October1,2008Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from sustainedexpressionofPak1shRNAsinRT4cellsleadstoinhibitionofPak1expression,resultingincellularsenescence(Fig.4E).Importantly,RT4cellstransientlytransfectedwithPak1siRNAs,whichshouldnotbesusceptibletomethylation-mediatedsilenc-ing,didnotproliferateduringthefirstfewdaysposttransfection(SupplementaryFig.S2A).ConsistentwiththenotionthatPak1isthedominantPakinRT4cells,cotransfectionofPak2siRNAswithPak1siRNAsfailedtofurtherreducethegrowthrateofRT4cells(SupplementaryFig.S2B).Takentogether,weconcludedthatRT4cellsrequirePak1forproliferationandquicklymovetosilencePak1shRNAexpressionthroughdenovomethylation.DiscussionWehaveshownforthefirsttimethatPak1ishighlyactivatedinprimaryschwannomasfromNF2patients.ThisisconsistentwithourhypothesisthatmerlinfunctionsasatumorsuppressorbyblockingPakactivation.Employingbothcellularandanimalmodels,wedirectlytestedthishypothesis.WefoundthatthesimultaneousknockdownofallthreePaksisrequiredtocounterthehyperproliferationandtumor-formingcapacityofNIH3T3cellsharboringtheNF2BBAallele.Takentogether,theseresultsvalidatePaksaspotentialtargetsforthedevelopmentofNF2therapeutics.PreviousstudieshavelinkedPak1tocancerandtransformationanduseofPakinhibitorstoreversecellulartransformationhavealsobeenreported(17–19).However,thesestudiesareinconclu-sive,astheinhibitorsusedarebroad-rangekinaseinhibitorsthatdonotspecificallyinhibitPaks.Therefore,theimportantnextstepistodevelopspecificPakinhibitorsandtestthemincellularandanimalmodelsofNF2.AnotherinterestingfindinginthisstudyisthatdifferentcelltypesresponddifferentlytoPak1inhibition.AlthoughknockdownofPak1isinconsequentialinNIH3T3cells(Fig.2),Pak1ablationinRT4cellsleadstogrowtharrest(Fig.4D;SupplementaryFig.S2).Inaddition,NIH3T3cellsmaintainedreducedPak1expressionmediatedbyPak1shRNAsevenafterover20passages(datanotshown),whereasRT4cellsquicklysilencedPak1shRNAviadenovomethylation(Fig.4AandB).ThesedifferencessuggestthatalthoughPak1isprobablythedominantPakinRT4cells,itfunctionsredundantlywithPak2andPak3inNIH3T3cells.However,becausePak1,2,and3arehighlyhomologous,especiallywithintheircatalyticdomains,itismostlikelythatanyPakinhibitorswillworkequallywellonallthreePakisoforms.Therefore,thesecelltypedifferencesinPakfunctionshouldnotaffecttheeffectivenessofPakinhibitors.Figure4.RatschwannomacellsaredependentonPak1expression.A,WesternblotanalysisofPak1expressioninRT4cellsatvariouspassagesafterinfectionwithlentivirusesharboringaPak1specificshRNA.RT4cellsinfectedwithemptylentivirusvectorwereusedascontrol.Actinservesasaninternalloadingcontrol.B,methylationanalysisofLenti-shPak1promoterinRT4cells.ThegenomicDNAwasisolatedfromRT4cellsatpassage6afterinfectionwithlentivirusesharboringaPak1-specificshRNAandsubjectedtobisulfiteconversion,methylation-specificPCRs,anddirectsequencing.*,cytosinesintheoriginalsequencethathavebeencompletelyorpartiallyconvertedtouracils;arrowheads,unconverted/methylatedcytosines.C,WesternblotanalysisofPak1expressioninRT4cellsinfectedwithemptylentivector( )orPak1shRNA(+)treatedwith5-aza.The5-azawasaddedtotheculturemediumat5ng/mLfinalconcentration.Thecellswereharvestedandanalyzedatday0,1,2,and3intothetreatment.D,assessmentofcellularproliferation.Cells(4104)wereplatedintriplicateinto12-wellplatesandcellswereharvestedandcountedatday0,1,2,3,and4.Thedataarerepresentativeofthreeindependentexperiments.Points,mean;bars,SD.E,imagesofRT4cellsinfectedwithvectororPak1shRNAafter3dofcultureinthepresence(+5-aza)orabsence( 5-aza)of5-aza.Inthebottompanel,RT4cellswerefirstfixedandstainedwithX-gal.ImagesweretakenusingNikonCoolpix995digitalcameraunderLeicaDM1Llightmicroscopeat10magnification.CancerResearchCancerRes2008;68:(19).October1,20087936www.aacrjournals.orgResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from Finally,virus-deliveredshRNAhavebeenproposedasapotentialtherapeutictoolintreatinghumandiseasessuchascancer(20).Asdescribedinthisstudy,anshRNAtargetinganessentialgene,inourcase,Pak1inRT4cells,canbesilenceddirectlybyDNAmethylation.FurtherresearchshouldbecarriedouttoinvestigatewhetherothercelltypescanalsousesimilarmechanismstosilencestablyintegratedforeignshRNAandhowfrequentlysucheventscanoccur.Addressingthesequestionswouldbeprudentbeforeanyfutureapplicationofsuchtechnologiesasatreatmentmodality.DisclosureofPotentialConflictsofInterestNopotentialconflictsofinterestweredisclosed.AcknowledgmentsReceived3/7/2008;revised7/14/2008;accepted7/22/2008.Grantsupport:DepartmentofDefenseNeurofibromatosisResearchProgram.C.YiisarecipientofRuthL.KirschsteinNRSAfellowship.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.WethankDr.JoanneThorvaldsenforadviceonbisulfitesequencing.ValidationofPaksasTargetsinNeurofibromatosiswww.aacrjournals.org7937CancerRes2008;68:(19).October1,2008References1.YohayKH.Thegeneticandmolecularpathogen-esisofNF1andNF2.SeminPediatrNeurol2006;13:21–6.2.KissilJL,JohnsonKC,EckmanMS,JacksT.Merlinphosphorylationbyp21-activatedkinase2andeffectsofphosphorylationonmerlinlocalization.JBiolChem2002;277:10394–9.3.XiaoGH,BeeserA,ChernoffJ,TestaJR.p21-activatedkinaselinksRac/Cdc42signalingtomerlin.JBiolChem2002;277:883–6.4.AlfthanK,HeiskaL,GronholmM,RenkemaGH,CarpenO.CyclicAMP-dependentproteinkinasephosphorylatesmerlinatserine518independentlyofp21-activatedkinaseandpromotesmerlin-ezrinhetero-dimerization.JBiolChem2004;279:18559–66.5.JinH,SperkaT,HerrlichP,MorrisonH.TumorigenictransformationbyCPI-17throughinhibitionofamerlinphosphatase.Nature2006;442:576–9.6.ShawRJ,PaezJG,CurtoM,etal.TheNf2tumorsuppressor,merlin,functionsinRac-dependentsignal-ing.DevCell2001;1:63–72.7.XiaoGH,GallagherR,ShetlerJ,etal.TheNF2tumorsuppressorgeneproduct,merlin,inhibitscellprolifer-ationandcellcycleprogressionbyrepressingcyclinD1expression.MolCellBiol2005;25:2384–94.8.KaempchenK,MielkeK,UtermarkT,LangmesserS,HanemannCO.UpregulationoftheRac1/JNKsignalingpathwayinprimaryhumanschwannomacells.HumMolGenet2003;12:1211–21.9.NakaiY,ZhengY,MacCollinM,RatnerN.TemporalcontrolofRacinSchwanncell-axoninteractionisdisruptedinNF2-mutantschwannomacells.JNeurosci2006;26:3390–5.10.KissilJL,WilkerEW,JohnsonKC,EckmanMS,YaffeMB,JacksT.Merlin,theproductoftheNf2tumorsuppressorgene,isaninhibitorofthep21-activatedkinase,Pak1.MolCell2003;12:841–9.11.MorrisonH,SperkaT,ManentJ,GiovanniniM,PontaH,HerrlichP.Merlin/neurofibromatosistype2sup-pressesgrowthbyinhibitingtheactivationofRasandRac.CancerRes2007;67:520–7.12.HirokawaY,TikooA,HuynhJ,etal.Acluetothetherapyofneurofibromatosistype2:NF2/merlinisaPAK1inhibitor.CancerJ2004;10:20–6.13.RubinsonDA,DillonCP,KwiatkowskiAV,etal.Alentivirus-basedsystemtofunctionallysilencegenesinprimarymammaliancells,stemcellsandtransgenicmicebyRNAinterference.NatGenet2003;33:401–6.14.BuchwaldG,HostinovaE,RudolphMG,etal.ConformationalswitchandroleofphosphorylationinPAKactivation.MolCellBiol2001;21:5179–89.15.ChongC,TanL,LimL,ManserE.ThemechanismofPAKactivation:auto-phosphorylationeventsinbothregulatoryandkinasedomainscontrolactivity.JBiolChem2001;22:22.16.JohnsonKC,KissilJL,FryJL,JacksT.CellulartransformationbyaFERMdomainmutantoftheNf2tumorsuppressorgene.Oncogene2002;21:5990–7.17.TangY,ChenZ,AmbroseD,etal.Kinase-deficientPak1mutantsinhibitRastransformationofRat-1fibroblasts.MolCellBiol1997;17:4454–64.18.VadlamudiRK,AdamL,WangRA,etal.Regulatableexpressionofp21-activatedkinase-1promotesanchor-age-independentgrowthandabnormalorganizationofmitoticspindlesinhumanepithelialbreastcancercells.JBiolChem2000;275:36238–44.19.HoweAK,JulianoRL.Regulationofanchorage-dependentsignaltransductionbyproteinkinaseAandp21-activatedkinase.NatCellBiol2000;2:593–600.20.LuPYXF,WoodleMC.InvivoapplicationofRNAinterference:fromfunctionalgenomicstotherapeutics.AdvGenet2005;54:117–42.Research. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 2008;68:7932-7937. Cancer Res(cid:160)(cid:160) Chunling Yi, Erik W. Wilker, Michael B. Yaffe, et al. (cid:160) Inhibition in Neurofibromatosis Type 2Validation of the p21-Activated Kinases as Targets for(cid:160) Updated version(cid:160)  http://cancerres.aacrjournals.org/content/68/19/7932Access the most recent version of this article at:(cid:160) MaterialSupplementary(cid:160)  http://cancerres.aacrjournals.org/content/suppl/2008/09/26/68.19.7932.DC1Access the most recent supplemental material at:(cid:160) (cid:160) (cid:160) (cid:160) (cid:160) Cited articles(cid:160)  http://cancerres.aacrjournals.org/content/68/19/7932.full.html#ref-list-1This article cites 20 articles, 10 of which you can access for free at:(cid:160) Citing articles(cid:160)  /content/68/19/7932.full.html#related-urlsThis article has been cited by 12 HighWire-hosted articles. Access the articles at:(cid:160) (cid:160) (cid:160) E-mail alerts related to this article or journal.Sign up to receive free email-alerts(cid:160) SubscriptionsReprints and (cid:160) .pubs@aacr.orgDepartment atTo order reprints of this article or to subscribe to the journal, contact the AACR Publications(cid:160) Permissions(cid:160) .permissions@aacr.orgDepartment atTo request permission to re-use all or part of this article, contact the AACR PublicationsResearch. on June 25, 2017. © 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from 